We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Phytopharm | PYM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 58.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 58.00 | 58.00 |
| Top Posts |
|---|
Posted at 26/9/2013 23:26 by aishah Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", or the "Company") today announces that terms have been agreed for the conditional acquisition (the "Acquisition") of IXICO Limited ("IXICO"), a medical technology and diagnostics company. The aggregate consideration for the Acquisition is to be satisfied by the initial issue of 8,014,403 New Ordinary Shares on Admission and the proposed issue of 465,350 New Ordinary Shares as a result of the outstanding share options under the IXICO unapproved share option share scheme. Based on the Phytopharm closing share price of 20 May 2013 immediately prior to its suspension, the aggregate consideration is valued at approximately GBP5.6 million. |
Posted at 23/9/2013 07:12 by skinny Portfolio company IXICO expands into digital healthcareImperial Innovations Group plc (AIM: IVO, "Innovations") portfolio company IXICO Limited, a medical imaging analysis company, is to be acquired by Phytopharm plc (AIM: PYM) in a proposed reverse takeover announced today. The enlarged Phytopharm group, to be renamed IXICO plc, will benefit from a strengthened balance sheet to grow its clinical trial services business and to bring new technology solutions to the diagnosis of dementia and other conditions. The newly-quoted IXICO plc will use the new ticker 'IXI'. Innovations maintains its support for IXICO and as part of this transaction has purchased a small parcel of shares; following completion of this transaction it will hold a 11.518% shareholding in IXICO plc. IXICO has established itself as a leading provider of medical imaging analysis services in the clinical trials market. It is expanding into the 'digital healthcare' space with products to support dementia diagnosis. Its vision is to build on its credibility internationally to position itself as a 'Brain Health Company' and to bring innovative technologies to those involved in researching and treating serious brain diseases enabling them to help patients more quickly. Maina Bhaman, Director of Healthcare Ventures at Innovations, will be joining the IXICO plc board on completion. |
Posted at 23/9/2013 07:11 by skinny Proposed acquisition of IXICO LimitedProposed Issue of up to 8,479,753 New Ordinary Shares in the Company Proposed change of name to IXICO plc Admission of the Enlarged Issued Share Capital to trading on AIM Renewal of Shareholder Authorities and Notice of General Meeting Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", or the "Company") today announces that terms have been agreed for the conditional acquisition (the "Acquisition") of IXICO Limited ("IXICO"), a medical technology and diagnostics company. The aggregate consideration for the Acquisition is to be satisfied by the initial issue of 8,014,403 New Ordinary Shares on Admission and the proposed issue of 465,350 New Ordinary Shares as a result of the outstanding share options under the IXICO unapproved share option share scheme. Based on the Phytopharm closing share price of 20 May 2013 immediately prior to its suspension, the aggregate consideration is valued at approximately £5.6 million. Following completion, it is expected that Phytopharm shareholders will own approximately 45 per cent and that IXICO shareholders will own approximately 55 per cent of the Fully Diluted Enlarged Issued Share Capital. In view of the size of IXICO in relation to the Company, the Acquisition is classified as a reverse takeover under the AIM Rules and is therefore conditional, inter alia, on the approval of Shareholders in a general meeting. A copy of the admission document along with the notice of General Meeting is being sent out to shareholders shortly and will be available on the Company's website www.phytopharm.com. The Directors of Phytopharm consider that IXICO will provide a platform from which to create value for Shareholders and will provide a different risk profile to the Company's business model. Upon completion of the Acquisition, Phytopharm plc will change its name to IXICO plc with the new ticker "IXI". |
Posted at 18/9/2013 07:28 by ewads From PYM Website:-'Application will be made to the London Stock Exchange plc for the Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the Ordinary Shares will become effective on or around 4 September 2013.' Anyone have an update? |
Posted at 24/7/2013 20:52 by gerhart No we're not going to be disappearing anywhere, just hope the shareholder with a foot in both camps (its in RNS) values their PYM buddies at least as much as the target buddies.On the RNS, same with lots of these, but the repetition is endless! |
Posted at 21/5/2013 09:36 by derekhales Thanks greedfear - Guess PYM s/h will lose some value in the RTO transfer, if/when it finally transpires. That's another thing, I'll bet it won't be quick! |
Posted at 21/5/2013 09:26 by greedfear Investors in PYM do not lose their investment. If you find this difficult to understand than you could compare this to PYM buying (the shares of) an another company and paying with PYM shares.{I like it. The new company (PYM + the other) keep the cash, are revenue generating while PYM tax losses can still be carry forward (provided the new shareholders in the new company hold less than 25%)} |
Posted at 21/5/2013 08:32 by derekhales MrsA /mm2 - grateful for your insight as to what might happen next. Will PYM shareholders lose their investment? |
Posted at 18/2/2013 07:12 by whereareallthemugpuntersyachts TOP Traders Thread !!!! - CRTOPINFO - 14 Feb 2013 - 14:53:59 - 214696 of 215709 PYM 10.39p paid against offer 10.25p. Not many in yet on here. News any day now. TOP Traders Thread !!!! - CR TOPINFO - 14 Feb 2013 - 14:53:10 - 214694 of 215709 Paying well over now PYM. I did tell yas at 8.6p. I think good news is leaking! TOP Traders Thread !!!! - CR TOPINFO - 14 Feb 2013 - 14:50:07 - 214690 of 215709 PYM paying 10.25p now. :))))))) TOP Traders Thread !!!! - CR TOPINFO - 14 Feb 2013 - 14:22:37 - 214657 of 215709 PYM going over 10p ! |
Posted at 25/11/2012 02:47 by gnomet2 Sorry if I seem a bit rude, but I've wearied of refuting irrational bull commentary and interpretation on biotech forums the OXB one in particularIn this case your figure suggests that you think PYM's products could be actual cures for the diseases that will corner their whole markets and do away with the need for other treatments. - and that PYM won't need to get development partners who'll siphon off most of the revenue in return for the huge spending needed to try and get the products to market. (And if things go well, PYM is such a small fry outfit I'd be surprised if it wasn't taken over way before anything got close to market anyway ). Acc to Edison Research , PEAK market share for PD is 8% and for glaucoma just 2%. - and the market has learned over the decades to apply a hefty discount to analysts' forecasts. Don't get me wrong here I quite fancy PYM's chances of getting through this phase II for Cogane, but there's obviously a big downside risk and as yet I don't want to commit. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
